Compare Mesoblast Limited (MESO) vs Williams Companies Inc (WMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Williams Companies Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Williams Companies Inc trades at $72.43 (market cap $88.48B). The key difference: Williams Companies Inc is far larger — about 50.6× Mesoblast Limited's market cap, and Williams Companies Inc pays a 2.9% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Williams Companies Inc for 58 Days on average.
| MESO | WMB | |
|---|---|---|
Market Cap | $1.75B | $88.48B |
Volume | 239,027 | 9,280,680 |
Sector | Health | Energy |
52-Week High | $20.96 | $79.40 |
52-Week Low | $13.19 | $56.51 |
Typical Hold Time | 14 Days | 58 Days |
Enterprise Value | $1.83B | $119.11B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Williams Companies (WMB) trades at $71.46, down 1.28% with a bullish technical signal and strong analyst support. The stock shows solid fundamentals with $11.95B revenue, 25.18% net margin, and consistent dividend growth. Recent earnings show mixed results with Q1 2026 beat but Q4 2025 and Q2 2026 misses. The company benefits from stable fee-based revenues in the midstream energy sector, positioning it well for AI-driven natural gas demand growth.
WMB presents a compelling investment case with 79% analyst buy ratings and $87.27 consensus target, offering 22% upside potential. Key opportunities include dividend growth strategy and exposure to rising natural gas demand from data centers. Risks include energy market volatility, high debt levels at 52% debt-to-asset ratio, and execution challenges in capital-intensive projects. The stock's valuation at 28.47 P/E appears reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
